This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by TAKIYYUDDIN, M. A. Articles by O’CONNOR, D. T. Search for Related Content PubMed PubMed Citation Articles by TAKIYYUDDIN, M. A. Articles by O’CONNOR, D. T.

Suppression of Chromogranin-A Release from Neuroendocrine Sources in Man: Pharmacological Studies^*

Department of Medicine, University of California, and Veterans Administration Medical Center San Diego, California 92161
Albert-Ludwigs-Universitat Freiburg, Germany

Address all correspondence and requests for reprints to: Marwan A. Takiyyuddin, M.D., Nephrology/Hypertension, Veterans Administration Medical Center (111H), 3350 La Jolla Village Drive, San Diego, California 92161.

Chromogranin-A (CgA) is an acidic soluble protein with a virtually ubiquitous occurrence in normal human neuroendocrine tissues. Of the many potential tissue sources of CgA immunoreactivity, which contribute to basal (unstimulated) circulating CgA? To explore this question we studied the effects of selective and nonselective suppression of secretion at several sites within the neuroendocrine system. Selective disruption of sympathetic outflow by trimethaphan decreased basal CgA by 25%, suggesting that sympathetic neurons contribute to circulating CgA. Plasma CgA in patients with unilateral and bilateral adrenalectomy fell within the range observed in normal subjects, weighing against the adrenal medulla as a major source of basal circulating CgA. Selective suppression of a variety of anterior and posterior pituitary cell types decreased plasma levels of the usual resident peptide hormones, but left plasma CgA unperturbed. After propranolol treatment, plasma CgA remained unaltered. Secretin suppressed plasma PTH and calcitonin, but did not alter plasma CgA levels. On the other hand, widespread nonselective suppression of a variety of neuroendocrine secretory cells by somatostatin decreased plasma CgA by 48%. Plasma catecholamines were unaltered by somatostatin infusion, suggesting that somatostatin inhibited CgA release from nonsympathoadrenal sources. During the infusion of somatostatin, the plasma epinephrine increment in response to insulin-induced hypoglycemia was maintained, and plasma CgA did not fall, nor did it rise after somatostatin cessation. Taken together, these findings suggest that somatostatin did not inhibit transport of stimulation-released CgA from the adrenal medulla to the circulation. In conclusion, although the adrenal medulla is the major tissue source of CgA immunoreactivity in man, other neuroendocrine sites, including sympathetic axons and multiple endocrine glands, appear to influence the basal circulating concentration of CgA.

^* This work was supported by the V.A., the NIH [HL-43275 (to M.A.T) and HL-35018 (to D.T.O)], and the National Kidney Foundation (M.A.T, Fellow).

Received March 29, 1990.

This article has been cited by other articles:

				T. Angelone, A. M. Quintieri, B. K. Brar, P. T. Limchaiyawat, B. Tota, S. K. Mahata, and M. C. Cerra The Antihypertensive Chromogranin A Peptide Catestatin Acts as a Novel Endocrine/Paracrine Modulator of Cardiac Inotropism and Lusitropism Endocrinology, October 1, 2008; 149(10): 4780 - 4793. [Abstract] [Full Text] [PDF]

				L. Taupenot, K. L. Harper, and D. T. O'Connor The Chromogranin-Secretogranin Family N. Engl. J. Med., March 20, 2003; 348(12): 1134 - 1149. [Full Text] [PDF]

				K. Tang, H. Wu, S. K. Mahata, L. Taupenot, D. J. Rozansky, R. J. Parmer, and D. T. O'Connor Stimulus-transcription Coupling in Pheochromocytoma Cells. PROMOTER REGION-SPECIFIC ACTIVATION OF CHROMOGRANIN A BIOSYNTHESIS J. Biol. Chem., November 8, 1996; 271(45): 28382 - 28390. [Abstract] [Full Text] [PDF]

				M. Pavlovic, P. Saiag, J.-P. Lotz, E. Marinho, T. Clerici, and V. Izrael Regression of Sclerodermatous Skin Lesions in a Patient With Carcinoid Syndrome Treated by Octreotide Arch Dermatol, October 1, 1995; 131(10): 1207 - 1209. [Abstract] [PDF]

				M. A. Takiyyuddin, R. J. Parmer, M. T. Kailasam, J. H. Cervenka, B. Kennedy, M. G. Ziegler, M.-C. Lin, J. Li, C. E. Grim, F. A. Wright, et al. Chromogranin A in Human Hypertension : Influence of Heredity Hypertension, July 1, 1995; 26(1): 213 - 220. [Abstract] [Full Text]